Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 323

Next Previous
Drug Profile

IBI 323

Alternative Names: Anti-LAG-3/PD-L1; Anti-LAG-3/PD-L1 bispecific antibody; IBI-323

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in China (IV, Infusion)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in China (IV, Infusion)
  • 14 Apr 2023 Phase-II clinical trials in Solid tumours (IV), prior to April 2023 (Innovent Biologics pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top